Response to Letter Re: Dose-individualisation of fluoropyrimidines based on pre-treatment serum uracil levels.

Saved in:
Bibliographic Details
Title: Response to Letter Re: Dose-individualisation of fluoropyrimidines based on pre-treatment serum uracil levels.
Authors: Heersche N; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Centre, Rotterdam, the Netherlands; Department of Clinical Chemistry, Erasmus University Medical Centre, Rotterdam, the Netherlands., Mathijssen RHJ; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Centre, Rotterdam, the Netherlands., Cats A; Department of Gastrointestinal Oncology, Div. of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Guchelaar HJ; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Centre, Leiden, the Netherlands., Knikman JE; Department of Global Public Health & Bioethics, Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, the Netherlands; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. Electronic address: J.E.Knikman@umcutrecht.nl.
Source: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2025 Nov 17; Vol. 230, pp. 115806. Date of Electronic Publication: 2025 Sep 22.
Publication Type: Letter
Journal Info: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE; In Process
Database: MEDLINE Ultimate
Description
ISSN:1879-0852
DOI:10.1016/j.ejca.2025.115806